Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications

Area of Science:

• Oncology
• Radiology
• Biochemistry

Background:

• Prostate cancer is a leading diagnosis in men.
• Bone scans are commonly used for staging, but can be costly.
• Serum prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.

Purpose of the Study:

• To evaluate the predictive accuracy of serum PSA for bone scan findings in newly diagnosed prostate cancer.
• To identify patient subgroups for whom bone scans may be unnecessary.
• To assess potential healthcare cost savings.

Main Methods:

• Analysis of data from two large-scale clinical studies.
• Correlation of serum PSA levels (Tandem-R and IMx assays) with bone scan results.
• Identification of patients with no skeletal symptoms and low PSA values.

Main Results:

• Serum PSA accurately predicted bone scan findings in 40% of patients with newly diagnosed, untreated prostate cancer.
• For patients with PSA ≤10 ng/mL and no skeletal symptoms, bone scans provided no additional useful information.
• Eliminating bone scans in this selected group could save approximately $38 million annually in the US.

Conclusions:

• Serum PSA is a reliable predictor of bone scan results in a significant proportion of early-stage prostate cancer patients.
• Omission of staging bone scans for selected asymptomatic patients with low PSA levels is clinically and economically justifiable.
• This approach can lead to substantial healthcare cost reductions as prostate cancer incidence rises.